Literature DB >> 33718216

Continuous Renal Replacement Therapy: A Review of Use and Application in Pediatric Hematopoietic Stem Cell Transplant Recipients.

Lama Elbahlawan1, John Bissler2,3, R Ray Morrison1.   

Abstract

Hematopoietic stem cell transplant (HSCT) is a curative therapy for malignant and non-malignant conditions. However, complications post-HSCT contribute to significant morbidity and mortality in this population. Acute kidney injury (AKI) is common in the post-allogeneic transplant phase and contributes to morbidity in this population. Continuous renal replacement therapy (CRRT) is used often in the setting of AKI or multiorgan dysfunction in critically ill children. In addition, CRRT can be useful in many disease processes related to transplant and can potentially improve outcomes in this population. This review will focus on the use of CRRT in critically ill children in the post-HSCT setting outside the realm of acute renal failure and highlight the benefits and applications of this modality in this high-risk population.
Copyright © 2021 Elbahlawan, Bissler and Morrison.

Entities:  

Keywords:  continuous renal replacement therapy (CRRT); fluid overload; hematopoietic (stem) cell transplantation (HCST); outcome; pediatrics; renal replacement therapy

Year:  2021        PMID: 33718216      PMCID: PMC7953134          DOI: 10.3389/fonc.2021.632263

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  60 in total

1.  KDIGO clinical practice guidelines for acute kidney injury.

Authors:  Arif Khwaja
Journal:  Nephron Clin Pract       Date:  2012-08-07

2.  Consensus Report by the Pediatric Acute Lung Injury and Sepsis Investigators and Pediatric Blood and Marrow Transplant Consortium Joint Working Committees on Supportive Care Guidelines for Management of Veno-Occlusive Disease in Children and Adolescents: Part 2-Focus on Ascites, Fluid and Electrolytes, Renal, and Transfusion Issues.

Authors:  Kris M Mahadeo; Jennifer McArthur; Roberta H Adams; Mohamed Radhi; Joseph Angelo; Asumthia Jeyapalan; Kathleen Nicol; Leon Su; Hanna Rabi; Jeffery J Auletta; Vinita Pai; Christine N Duncan; Robert Tamburro; Christopher C Dvorak; Rajinder P S Bajwa
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-17       Impact factor: 5.742

3.  Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.

Authors:  Gabriela Rondón; Rima M Saliba; Julianne Chen; Celina Ledesma; Amin M Alousi; Betul Oran; Chitra M Hosing; Partow Kebriaei; Issa F Khouri; Elizabeth J Shpall; Uday R Popat; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-24       Impact factor: 5.742

4.  Continuous renal replacement therapy and its impact on hyperammonaemia in acute liver failure.

Authors:  Stephen Warrillow; Caleb Fisher; Heath Tibballs; Michael Bailey; Colin McArthur; Pia Lawson-Smith; Bheemasenachar Prasad; Matthew Anstey; Bala Venkatesh; Gemma Dashwood; James Walsham; Andrew Holt; Ubbo Wiersema; David Gattas; Matthew Zoeller; Mercedes García Álvarez; Rinaldo Bellomo
Journal:  Crit Care Resusc       Date:  2020-06       Impact factor: 2.159

5.  Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure.

Authors:  Filipe S Cardoso; Michelle Gottfried; Shannan Tujios; Jody C Olson; Constantine J Karvellas
Journal:  Hepatology       Date:  2017-12-26       Impact factor: 17.425

6.  Acute Kidney Injury in Pediatric Patients Receiving Allogeneic Hematopoietic Cell Transplantation: Incidence, Risk Factors, and Outcomes.

Authors:  Kyung-Nam Koh; Anusha Sunkara; Guolian Kang; Amanda Sooter; Daniel A Mulrooney; Brandon Triplett; Ali Mirza Onder; John Bissler; Lea C Cunningham
Journal:  Biol Blood Marrow Transplant       Date:  2017-11-28       Impact factor: 5.742

7.  Epidemiology and Outcome of Critically Ill Pediatric Cancer and Hematopoietic Stem Cell Transplant Patients Requiring Continuous Renal Replacement Therapy: A Retrospective Nationwide Cohort Study.

Authors:  Paulien A M A Raymakers-Janssen; Marc R Lilien; Dick Tibboel; Martin C J Kneyber; Sandra Dijkstra; Job B M van Woensel; Joris Lemson; Karlien Cransberg; Marry M van den Heuvel-Eibrink; Roelie M Wösten-van Asperen
Journal:  Crit Care Med       Date:  2019-11       Impact factor: 7.598

8.  Timing of continuous renal replacement therapy in patients with septic AKI: A systematic review and meta-analysis.

Authors:  Yuting Li; Hongxiang Li; Dong Zhang
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

9.  Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.

Authors:  Victoria Gutgarts; Tania Jain; Junting Zheng; Molly A Maloy; Josel D Ruiz; Martina Pennisi; Edgar A Jaimes; Miguel-Angel Perales; Jaffer Sathick
Journal:  Biol Blood Marrow Transplant       Date:  2020-02-20       Impact factor: 5.742

Review 10.  Intensity of continuous renal replacement therapy for acute kidney injury.

Authors:  Alicia I Fayad; Daniel G Buamscha; Agustín Ciapponi
Journal:  Cochrane Database Syst Rev       Date:  2016-10-04
View more
  2 in total

Review 1.  Acute kidney injury in pediatric hematopoietic cell transplantation: critical appraisal and consensus.

Authors:  Rupesh Raina; Rolla Abu-Arja; Sidharth Sethi; Richa Dua; Ronith Chakraborty; James T Dibb; Rajit K Basu; John Bissler; Melvin Bonilla Felix; Patrick Brophy; Timothy Bunchman; Khalid Alhasan; Dieter Haffner; Yap Hui Kim; Christopher Licht; Mignon McCulloch; Shina Menon; Ali Mirza Onder; Prajit Khooblall; Amrit Khooblall; Veronika Polishchuk; Hemalatha Rangarajan; Azmeri Sultana; Clifford Kashtan
Journal:  Pediatr Nephrol       Date:  2022-02-28       Impact factor: 3.651

2.  Safety and efficacy of fluvoxamine in COVID-19 ICU patients: An open label, prospective cohort trial with matched controls.

Authors:  Martina Calusic; Robert Marcec; Lea Luksa; Ivan Jurkovic; Natasa Kovac; Slobodan Mihaljevic; Robert Likic
Journal:  Br J Clin Pharmacol       Date:  2021-12-01       Impact factor: 3.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.